Amicus follows Sanofi with disappointing pivotal Pompe data, casting further doubt on approvals.
And the move will shake up the orthopaedic robotics scene.
Sarepta’s first ever controlled study, of a Duchenne muscular dystrophy gene therapy, brings the markets down to earth.
The company has spent five years buying in discontinued projects, and at last has managed to sell one of these on at a nice profit.
Early 2021 will see rare diseases dominate for biotech, with Sarepta revealing key data on its gene therapy play.
With Gilead's big sellers forecast to drift, investors turn to its newer projects but find little comfort.